Value in cancer drug spending: assessing the clinical risks and benefits from a decade’s worth of innovation

Salas-Vega, S. & Mossialos, E. LSE Health & Social Care Blog. Published online: 5 January 2017

figure-2-1-1024x979

Image source: LSE

To shed light on the clinical risks and benefits from new cancer medicines, we took a narrative synthesis approach to review regulatory assessments of the impact on overall survival, quality of life, and safety from all cancer medicines newly licensed in the US and EU between 2003-2013. For this, two researchers evaluated appraisals from English (National Institute of Health and Care Excellence, NICE), French (Haute Autorité de Santé, HAS) and Australian (Pharmaceutical Benefits Advisory Committee, PBAC) health technology assessment (HTA) agencies that were published through May 2015.

We find that while most new cancer drugs approved between 2003 and 2013 extended overall survival or improved the quality of life of cancer patients, their clinical benefits vary widely. Improvements in overall survival and quality of life also often come at the cost of safety, and there are reasons to question whether claims of clinical benefits have been matched by those observed in real-world settings.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s